HeraMED
HeraMED is an ASX-listed digital health company offering the AI-powered HeraCARE platform and FDA-cleared HeraBEAT fetal monitor. It serves hospitals and healthcare systems via subscription SaaS, remote monitoring, telehealth, and AI-driven clinical and patient engagement tools.
- Company typePublic
- Founded2011
- HeadquartersNetanya, Israel
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What HeraMED does
HeraMED is an ASX-listed (HMD) digital health company that develops and sells an AI-powered platform for women's healthcare spanning fertility, pregnancy, postpartum, menopause, and chronic care. Its core offering combines the FDA-cleared HeraBEAT fetal heart rate monitor with the HeraCARE software platform, which integrates remote patient monitoring, embedded telehealth with ambient scribing, an AI Clinician Dashboard, and an AI Patient Engagement App driven by a Virtual Companion trained in women's health. The company primarily serves large healthcare systems, hospital networks, and women's health clinicians on a B2B basis, with active deployments at named institutions including Broward Health, Lee Health, Sheba Medical Center, Joondalup Health Campus, Gold Coast Hospital, and Telstra Health, as well as a partnership with Philips to bring a maternity solution to the US market.
HeraMED's business model rests on three revenue streams: enterprise SaaS subscriptions for the HeraCARE platform (multi-year contracts such as a 2-year Broward Health agreement and a 3-year e-Lovu agreement), hardware sales of the HeraBEAT device, and professional services tied to pilot deployments and clinical trials. Its go-to-market blends direct enterprise field sales to large hospital networks with channel partnerships (Telstra Health for Australia, Philips for the US, Garmin Health for wearable data integration, Founda Health for European exploration, GPEx for regional distribution). The motion is characteristically enterprise health-tech: paid pilots convert into multi-year commercial agreements over extended sales cycles.
Founded in 2011, HeraMED is headquartered in Netanya, Israel, with US operations in Tustin, California, and an Australian headquarters in Hawthorn East, Victoria. The company operates with 11-50 employees and has raised approximately AUD 22 million across multiple placements and a convertible note since 2021, indicating it remains cash-consumption negative and dependent on recurring equity capital to fund US expansion and its next-generation AI roadmap.
HeraMED firmographics
Firmographics- Name
- HeraMED
- Legal name
- Hera Med Ltd.
- Website
- https://hera-med.com
- Company type
- Public
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- HeraMED is an ASX-listed digital health company offering the AI-powered HeraCARE platform and FDA-cleared HeraBEAT fetal monitor. It serves hospitals and healthcare systems via subscription SaaS, remote monitoring, telehealth, and AI-driven clinical and patient engagement tools.
- Ownership category
- akta.pro rank
HeraMED industry classification
Industry- Product category
- Digital Maternity / Women's Health SaaS
- NAICS
- Home Health Care Services (621610), Custom Computer Programming Services (541511)
- SIC
- Services-Home Health Care Services (8082), Services-Prepackaged Software (7372)
- akta.pro primary industry
- Pregnancy & Prenatal Care Telehealth (OB tele-visits, prenatal monitoring) (HLALAHAC)
- akta.pro secondary industries
- Patient Engagement, Education & Messaging Platforms (portal/CRM integrated) (HLALABAJ), Chronic Condition Virtual Care & Disease Management (Payer-Sponsored) (HLALACAE), Women’s Health & Fertility Therapeutics (Digital) (HLACANAK)
Keywords
Where HeraMED is headquartered
LocationHeadquarters
- HQ city
- Netanya
- HQ country
- Israel
- HQ region
- Middle East
Offices4 records
Markets served
HeraMED business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- SaaS/Software Platform Subscription: Subscription-based SaaS model for healthcare organizations accessing the HeraCARE platform. Healthcare providers pay recurring fees for access to the AI-powered women's health platform, remote monitoring, and clinician tools. Multi-year agreements with health systems suggest enterprise subscription pricing.
- Hardware Sales (HeraBEAT): Sale of FDA-cleared fetal monitoring devices (HeraBEAT) to healthcare providers and potentially directly to consumers for home monitoring.
- Professional Services: Implementation and training services for healthcare organization deployment. Pilot programs and clinical trial partnerships generate service revenue.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Multi-year contract | Enterprise healthcare organizations (hospitals, health systems) |
Go-to-market motion3 records
Distribution channels5 records
Marketing channels5 records
HeraMED product offering
Product offeringCore offering
HeraMED develops and sells the HeraCARE digital health platform, an AI-powered, SaaS-based solution for women's health spanning fertility, pregnancy, postpartum, menopause, and chronic care. It combines remote monitoring, embedded telehealth, AI-driven patient engagement (virtual companion), and an AI clinician dashboard with ambient scribing, paired with the FDA-cleared HeraBEAT fetal heart rate monitor for home and clinical use. The offering is delivered as enterprise subscriptions to hospitals, health systems, and channel partners such as Telstra Health and Philips.
Product overview
HeraMED offers an intelligent digital health platform for women combining AI-powered clinical tools, an empathetic Virtual Companion, and remote monitoring capabilities. The core HeraCARE Platform spans women's life stages from fertility through pregnancy, postpartum, menopause, and chronic care. Key products include the FDA-cleared HeraBEAT fetal monitor for home-based prenatal monitoring, the AI Clinician Dashboard with ambient scribing for automated clinical documentation, the AI Patient Engagement App with a Virtual Companion for personalized patient support, and integrated telehealth functionality. The platform delivers 50% lower postpartum readmissions, 50% fewer in-person visits, and hypertension detection at 25 weeks or earlier.
Differentiator
Problem solved
Functional benefit
Brands
- HeraBEAT: FDA-cleared fetal heart rate monitor device with upgraded TGA regulatory classification
- HeraCARE
- e-Lovu
Products and services
- HeraCARE Platform AI-powered, SaaS digital health platform for women's health spanning fertility, pregnancy, postpartum, menopause, and chronic care, combining remote monitoring, embedded telehealth, AI-driven patient engagement, and a clinician dashboard with ambient scribing; sold as multi-year enterprise subscriptions to hospital networks and health systems such as Broward Health, Lee Health, Sheba Medical Center, and Joondalup Health Campus.
- HeraBEAT FDA-cleared fetal heart rate monitor providing medical-grade remote prenatal monitoring for use at home and in clinical settings; receives TGA regulatory classification upgrade in Australia. Distributed through hospital deployments and channel partners such as Philips and Telstra Health.
Quantifiable outcome
- 50% lower postpartum readmissions
- +5 more outcomes
Companies that use HeraMED
Customer profileNamed customers10 records
Segments3 records
Ideal customer profiles2 records
HeraMED technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability7 records
Feature5 records
HeraMED partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered core and minor.
- Lee HealthcoreHeraMED partnered with Lee Health for a digital maternity solution. Lee Health is one of the largest public health systems in the US, representing significant market access for HeraMED's platform.
- Philips (Koninklijke Philips N.V.)coreHeramed partnered with Philips to develop a US maternity solution. This is a significant strategic partnership with a global leader in healthcare technology for maternity care deployment in the US market.
- RMIT UniversityminorGrant Awarded to Advance AI Maternity Care with RMIT & DHCRC (Digital Health Cooperative Research Centre) (Jun 2025). Academic research partnership.
- Garmin HealthcoreStrategic Collaboration Agreement with Garmin Health (Feb 2025). Integration of wearable device data into HeraCARE platform for enhanced monitoring capabilities.
- MetronomicminorLOI with Metronomic to develop postpartum care solution in US (Nov 2024). Metronomic focuses on chronic disease management.
- Founda HealthminorLetter of Intent with Founda Health to explore European market expansion. Founda Health provides digital health infrastructure in Europe.
- University of Technology Sydney (UTS)minorUTS Strategic Partnership announced (Jul 2024). Academic partnership for research and development in women's health technology.
- GPExminorStrategic collaboration and commercial agreement with GPEx (Jan 2024). GPEx is an Australian health technology distributor.
- WingwomenminorUSA-based Wingwomen signs MoU to launch 'Cardio Care' (Dec 2023). Women's health-focused company.
- FemBridgeminorMOU signed with US-based FemBridge for maternity care solution (Dec 2023). Binding Strategic Partnership Agreement signed (Mar 2024).
- Telstra HealthcoreSigned Partner Agreement with Telstra Health (Nov 2023). Telstra Health soft launched HeraCARE (Jun 2024). Telstra Health is a major Australian health technology company providing digital health solutions.
- e-LovucoreHMD & e-Lovu Health Partnership for HeraCARE Deployment US (Jul 2022). E-Lovu signs first 3-year commercial agreement (Jun 2023). Successful first phase commercial rollout (Feb 2023).
Scale indicators7 records
Recent moves8 records
Expansion highlights6 records
HeraMED competitors and assessment
Company assessmentDirect peers
- Babyscripts: US-based maternal health platform offering remote pregnancy monitoring and patient engagement for health systems. Closely comparable to HeraCARE on the pregnancy-monitoring use case, B2B health-system GTM, and outcomes-driven value proposition.
- Ovia Health (by Labcorp): Digital women's health platform covering fertility, pregnancy and postpartum, now owned by Labcorp. Comparable as an AI-enabled, life-stage-spanning women's health platform sold into payers and employers.
- Maven Clinic: Virtual care clinic for women and families spanning fertility, maternity, postpartum and pediatrics. Directly comparable in B2B payer/employer GTM and life-stage breadth to HeraMED's HeraCARE scope.
- Wildflower Health: Enterprise women's health platform sold to health plans and providers for maternity and family health journeys. Comparable to HeraMED's payer/provider B2B motion and life-stage patient-engagement focus.
- Mahmee: Maternal and infant health platform providing pregnancy and postpartum support via care coordination and telehealth. Comparable as a maternal-health-focused digital health company with health-system partnerships.
- Delfina Care: AI-powered pregnancy care platform for providers and payers, focused on remote monitoring and risk detection. Comparable to HeraCARE on AI-driven maternal monitoring, B2B health-plan GTM, and outcomes analytics.
Emerging players
- Progyny: Benefits management platform focused on fertility, women's reproductive health and family building for employers. Comparable in women's health life-stage coverage and B2B employer/plan channel, though narrower scope (no pregnancy monitoring).
- Mirvie: Pioneering RNA-based early detection of pregnancy complications. Comparable as a pregnancy-health technology company pursuing clinical evidence and provider partnerships in the same maternal care category.
Broad incumbents
- Philips (maternal health division): Global healthcare technology incumbent with a maternal and fetal monitoring portfolio and a co-development partner of HeraMED for US maternity. Comparable as both a potential competitor and incumbent buyer/partner with deeper US hospital reach.
- Teladoc Health: Large virtual care incumbent operating across primary care, chronic conditions and specialty telehealth for employers and health plans. Comparable as a broader incumbent that could bundle women's health into enterprise contracts HeraMED also targets.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
HeraMED social profiles
Digital presenceHeraMED compliance and trust
Trust signalCompliance2 records
HeraMED financial estimates
Financial estimateRevenue estimate
Valuation estimate
HeraMED leadership team
Management profileNumber of profiles
Profiles11 records
HeraMED funding detail
Funding detailFunding overview
Funding rounds2 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
HeraMED M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about HeraMED
What does HeraMED do?
HeraMED develops and sells the HeraCARE digital health platform, an AI-powered, SaaS-based solution for women's health spanning fertility, pregnancy, postpartum, menopause, and chronic care. It combines remote monitoring, embedded telehealth, AI-driven patient engagement (virtual companion), and an AI clinician dashboard with ambient scribing, paired with the FDA-cleared HeraBEAT fetal heart rate monitor for home and clinical use. The offering is delivered as enterprise subscriptions to hospitals, health systems, and channel partners such as Telstra Health and Philips.
Is HeraMED a public or private company?
HeraMED is a public company. It is classified as public and is currently operating.
When was HeraMED founded?
HeraMED was founded in 2011. It employs 11 to 50 people.
Where is HeraMED based?
HeraMED is headquartered in Netanya, Israel, in the Middle East region.
How does HeraMED make money?
Three revenue lines are on record. SaaS/Software Platform Subscription is the primary driver. The others are hardware Sales (HeraBEAT) and professional Services.
Who are HeraMED's main competitors?
Direct peers on record are Babyscripts, Ovia Health (by Labcorp), Maven Clinic, Wildflower Health, Mahmee and Delfina Care. Emerging players are Progyny and Mirvie. Broad incumbents are Philips (maternal health division) and Teladoc Health.
Does HeraMED have an API?
No public API is recorded for HeraMED.
What industry is HeraMED in?
HeraMED's product category is Digital Maternity / Women's Health SaaS. Its primary akta.pro industry code is HLALAHAC, Pregnancy & Prenatal Care Telehealth (OB tele-visits, prenatal monitoring), with a secondary code of HLALABAJ, Patient Engagement, Education & Messaging Platforms (portal/CRM integrated). Its NAICS code is 621610 and its SIC code is 8082.